Christopher M Reynolds
Overview
Explore the profile of Christopher M Reynolds including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
536
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reynolds C, Fiebig O, Marroquin A, Glaid A, Chokhany K, Zdenek R, et al.
J Am Chem Soc
. 2025 Mar;
147(10):8386-8397.
PMID: 40032528
Gouy-Chapman theory predicts that salt screening and modulating the interfacial charge density should strongly influence the apparent dissociation constant, , between Cu and negatively charged phosphatidylserine (PS) lipids in supported...
2.
Meric-Bernstam F, Rothe M, Mangat P, Garrett-Mayer E, Gutierrez R, Ahn E, et al.
JCO Precis Oncol
. 2023 Dec;
7:e2300385.
PMID: 38096472
Purpose: The Targeted Agent and Profiling Utilization Registry Study is a phase II basket study evaluating antitumor activity of commercially available targeted agents in patients with advanced cancers with genomic...
3.
Rohatgi N, Rothe M, Mangat P, Garrett-Mayer E, Meric-Bernstam F, Pisick E, et al.
JCO Precis Oncol
. 2023 Dec;
7:e2300279.
PMID: 38039429
Purpose: The Targeted Agent and Profiling Utilization Registry Study is a phase II basket study evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancers with...
4.
Durie B, Hoering A, Sexton R, Abidi M, Epstein J, Rajkumar S, et al.
Blood Cancer J
. 2020 May;
10(5):53.
PMID: 32393732
SWOG S0777, a randomized phase III trial, compared bortezomib, lenalidomide and dexamethasone (VRd) with lenalidomide and dexamethasone (Rd). This updated analysis includes 460 patients evaluable for survival endpoints: 225 eligible...
5.
Roberts N, Burleson M, Burmeister L, Bushnell M, Epstein D, Todd M, et al.
Psychol Serv
. 2018 Aug;
17(1):33-45.
PMID: 30070550
This study investigated the feasibility and preliminary effectiveness of a pilot program designed to address subjective memory complaints among Veterans. The program, Brain Boosters, consisted of 10 once-weekly group sessions,...
6.
Durie B, Hoering A, Abidi M, Rajkumar S, Epstein J, Kahanic S, et al.
Lancet
. 2016 Dec;
389(10068):519-527.
PMID: 28017406
Background: Lenalidomide plus dexamethasone is a reference treatment for patients with newly diagnosed myeloma. The combination of the proteasome inhibitor bortezomib with lenalidomide and dexamethasone has shown significant efficacy in...
7.
DeLong R, Reynolds C, Malcolm Y, Schaeffer A, Severs T, Wanekaya A
Nanotechnol Sci Appl
. 2013 Nov;
3:53-63.
PMID: 24198471
Nanotechnology has virtually exploded in the last few years with seemingly limitless opportunity across all segments of our society. If gene and RNA therapy are to ever realize their full...
8.
Ayash L, Ratanatharathorn V, Braun T, Silver S, Reynolds C, Uberti J
Am J Hematol
. 2006 Sep;
82(1):6-14.
PMID: 16986128
Limited data are available for adults undergoing unrelated donor (URD) BMT for AML using chemotherapy-only preparative regimens. Previous studies incorporated irradiation, included adults and children, and excluded secondary leukemia. Herein...
9.
Dawson L, Saito N, Ratanatharathorn V, Uberti J, Adams P, Ayash L, et al.
Int J Radiat Oncol Biol Phys
. 2004 Apr;
59(1):208-18.
PMID: 15093918
Purpose: This Phase I study was designed to evaluate the tolerability of involved-field radiotherapy (IFRT) to areas of persistent disease in patients with high-risk Hodgkin's disease and non-Hodgkin's lymphomas before...